Investigation of the Relationship Between Inherited Thrombophilia and Novel Coronavirus Pneumonia

Abstract

Aim: This study aimed to investigate the relationship between severe novel coronavirus pneumonia (NCP) and hypercoagulable conditions that predispose patients to thrombosis such as the prothrombin gene ( F2) rs1799963 (G20210A), factor V Leiden ( F5) rs6025 (G1691A) and PAI-1 (rs1799768). Patients: NCP-diagnosed 62 previously healthy patients were enrolled for the investigation of the thrombophilia-related polymorphisms. Materials & methods: The frequency of genotypes were compared with healthy control group frequencies from other studies. Results: There were no statistically significant differences between the severe patient group and the healthy population regarding the investigated single nucleotide polymorphisms (SNPs). Conclusion: This study is the first to rule out the relationship of rs1799963, rs6025 and rs1799768 with severe NCP.

Possible effect of genetic background in thrombophilia genes on clinical severity of patients with coronavirus disease-2019: A prospective cohort study

“…[12][13][14] Few studies have been conducted on the relationship between COVID-19 and congenital coagulation disorders or the presence of polymorphisms that cause thrombophilia. 4,[14][15][16][17] In the present study, the relationship between the severity of the COVID-19 clinical picture and some polymorphisms that cause thrombophilia were investigated. Factor V, one of the coagulation factors, has one of the most important roles in coagulation factors.…”

“…DIC has been associated with abnormal coagulation, thrombus, and poor prognosis. 1,3 Studies on factors that cause different clinical pictures among infected patients are very limited 4 . Microvascular embolisms and coagulation disorders worsen the clinical picture, especially in patients who need intensive care, and death is observed more frequently in patients who develop coagulopathy.…”

“…Thromboembolic events are thought to develop in the course of COVID-19 by various mechanisms; (i) development of vascular microthrombotic disease in sepsis, (ii) development of endothelial damage by complement activation, (iii) activation of the inflammatory and microthrombotic pathway, and (iv) stasis resulting from inactivity during the hospitalization period of the patients. 4,5 Also, in the advanced stages of the disease, diffuse intravascular coagulation, whose pathophysiology is complex and multifactorial, was observed. Anticoagulants and antiplatelet drugs are used in the treatment of some of the COVID-19 patients.…”

“…6 There have been some studies showing a relationship between thrombophilia and disease severity in COVID-19 patients. [3][4][5] In this study, it was aimed to investigate the relationship between the genes predisposing to thrombophilia in patients with COVID-19 with the clinic of the disease and the effect on mortality and morbidity in these patients.…”

Multi-factorial Mechanism Behind COVID-19 Related Thrombosis

“…The studies concerning the association of thrombophilic mutations and novel coronavirus virus pneumonia showed conflicting results. Kiraz et al (2021) reported no statistically significant difference in the frequency of these polymorphisms in patients with severe COVID-19 pneumonia and the healthy population ( 32 ). Conversely, Conversely, Appenzeller et al presented a case of a previously healthy 21-year-old male with extensive thromboembolism in the absence of obvious thrombophilic risk factors; the thrombophilia screening revealed the presence of the heterozygous factor V Leiden mutation, and despite the absence of clinical presentations of COVID-19, he tested positive ( 33 ).…”